Forest Laboratories, Inc. and Cypress Bioscience, Inc. announced today that Savella , a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th.
Read full story
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of … (PR Newswire via Yahoo! Finance)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. announced today that they expect to ship Sav...
- Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Commercial Availability Of Savella (BioresearchOnline)
Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced today ...
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for … (PR Newswire via Yahoo! Finance)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced positive top-line results fr...
- Forest and Cypress Announce FDA Approval of Savella for the Management of Fibromyalgia
- Forest Laboratories and Cypress Bioscience Announce Study Shows…
Category: 
21 April 2009
Sorry, no comments yet.